pSV2Neo, a plasmid that contains the wild-type simian virus 40 (SV40) origin of replication (ori), is widely used in mammalian cell transfection experiments. We observed that pSV2Neo transforms two nontumorigenic SV40-immortalized human uroepithelial cell lines (SV-HUC and CK/SV-HUC2) to G418 resistance (G418r) at a frequency lower than that at which it transforms SV-HUC tumorigenic derivatives (T-SV-HUC). Transient expression studies with the chloramphenicol transferase assay showed that these differences could not be explained by differences in Neo gene expression. However, when we replaced the SV40 ori in pSV2Neo with a replication-defective ori to generate G13.1Neo and G13.1'Neo, the G418' transformation frequency of the SV40-immortalized cell lines was elevated. Because SV40 T antigen stimulates replication at its ori, we tested plasmid replication in these transfected cell lines. The immortalized cell lines that showed low G418r transformation frequencies after transfection with pSV2Neo showed high levels of plasmid replication, while the T-SV-HUC that showed high G418r transformation frequencies failed to replicate pSV2Neo. To determine whether differences in the status of the T-antigen gene contributed to the phenomenon, we characterized the T-antigen gene in these cell lines. The results showed that the T-SV-HUC had sustained mutations in the T-antigen gene that would interfere with the ability of the T antigen to stimulate replication at its ori. Most T-SV-HUC contained a super-T-antigen replication-defective ori that apparently resulted from the partial duplication of SV40 early genes, but one T-SV-HUC had a point mutation in the ori DNA-binding domain of the T-antigen gene. These results correlate with the high G418' transformation frequencies with pSV2Neo in T-SV-HUC compared with SV-HUC and CK/SV-HUC2. Furthermore, these results suggest that alterations in SV40 T antigen may be important in stabilizing human cells immortalized by SV40 genes that contain the wild-type SV40 ori, thus contributing to tumorigenic transformation. This is the first report of a super T antigen occurring in human SV40-transformed cells.
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In vitro transformation systems provide important models with which to study complex biochemical and genetic changes that contribute to multistep tumorigenesis. Because of the limited life span of normal diploid cells in culture, a necessary first step in establishing such models is cell immortalization (5) . Unlike in rodent cells, immortalization of human cells in culture does not occur spontaneously and has been difficult to achieve reproducibly with chemical carcinogens (12, 18, 53) . However, human cell immortalization can be achieved routinely with small DNA tumor viruses or their oncoprotein genes (5) . For example, immortalization of many human epithelial cell types has been reported with simian virus 40 (SV40) or the SV40 T antigen gene (6, 8, 20, 29, 40) . In contrast to observations made with rodent cells, in which SV40 immortalization is usually accompanied by tumorigenic transformation, SV40-immortalized human epithelial cells usually have not undergone tumorigenic transformation (5, 19, 52) . Therefore, SV40-immortalized human cell lines have been considered useful models for studying the ability of various chemicals, irradiation, and oncogenes to cause tumorigenic transformation or progression in different human cell types (44) .
Our laboratory has developed two multistep in vitro-in vivo transformation systems with SV40 (wild-type virus)-* Corresponding author.
infected and SV40 T antigen gene (plasmid)-transfected immortalized human uroepithelial cells (HUC), the SV-HUC (8) and CK/SV-HUC2 (21) transformation systems, respectively. Tumorigenic transformation and/or neoplastic progression of SV-HUC and CKISV-HUC2 has been achieved after exposure of cells in vitro to chemical carcinogens (2, 42) or transfection with the EJIras human bladder cancer oncogene (7, 21, 39 (17, 23, 41) . SV40 T antigen forms complexes with several cellular proteins, including DNA polymerase (49) and two tumor suppressor gene products, pRB (11) and p53 (27, 31, 37, 49 (20a) . Most relevant to the present report is the observation that SV40 T antigen initiates DNA replication from its ori (10, 22, 47) . If unchecked, virus replication leads to cell lysis and cell death in permissive cell types (52) . Cells that are permissive or semipermissive for SV40 but survive infection, including monkey and human cells, must by definition generate mechanisms to limit virus replication. In monkey and human cells, these mechanisms have included selection for mutations in the T-antigen gene that inactivate its ability to initiate replication (14, 15, 48) .
We report here that similar types of T-antigen mutations are generated in SV40-immortalized HUC that have undergone tumorigenic transformation. We transfected a pSV2 Neo-derived EJ/ras expression vector into SV-HUC and CK/SV-HUC2. The Neo gene in this construct is controlled by the SV40 early gene promoter and results in G418 resistance (G418') (50) . We observed a very low efficiency of transformation to G418' by pSV2Neo in SV-HUC and CK/ SV-HUC2 compared with T-SV-HUC, the chemically transformed tumorigenic derivatives of SV-HUC, and also compared with control cell lines that do not contain SV40 genes.
We found that T antigen stimulates replication from the SV40 ori of pSV2Neo-transfected SV40-immortalized cell lines, resulting in a low G418' transformation frequency with this vector. However, similar plasmid replication was not observed in T-SV-HUC, the isogenic tumorigenic derivatives of SV-HUC. We discovered that these T-SV-HUC had sustained mutations in the T-antigen gene, including those generating a super T antigen, that would interfere with their ability to stimulate replication from the SV40 ori.
MATERIALS AND METHODS
Cells. Two SV40-immortalized cell lines, SV-HUC and CK/SV-HUC2, were used in this study. The methods of establishment and the characteristics of these cell lines have been described (8, 21, 42) . In brief, SV-HUC was established after infection of cultured normal ureteral HUC with wildtype SV40 (8) . At passage 15 (pi5), SV-HUC had one SV40 integration site, was near diploid karyotypically, expressed SV40 T antigen, and did not produce infectious SV40 (8) . CK/SV-HUC2 was established from a similar HUC culture but after transfection with a plasmid carrying SV40 early genes with an ori-negative (ori-) expression element (21) . At p23, CKISV-HUC2 also had one SV40 integration site and expressed SV40 T antigen, but this cell line showed losses of chromosomes 3p, llp, and 13q (21) . Neither SV-HUC (p15) nor CK/SV-HUC2 (p23) was tumorigenic when inoculated into athymic nude mice (8, 21) .
However, exposure of SV-HUC to chemical carcinogens, including the polycyclic hydrocarbon carcinogen 3-methylcholanthrene, resulted in tumorigenic transformation, which allowed us to generate the series of SV-HUC isogenic tumorigenic derivatives, Ti, T2, T7, T9, T10, and T16 (42) , that were also used in this study. Cell lines derived from a subcutaneous tumor transplant of Ti, TT1, and a lung tumor metastasis from a tail vein inoculation of Ti, mTT1, were also used in this study. We used as controls in this study two carcinoma HUC lines, T24 and 647V, that were derived from clinical bladder cancers, and also the NIH 3T3 rodent fibroblast cell line. None of these control cell lines contains the SV40 genome. All cells were cultured in 100-mm plastic petri dishes (PiOO; Corning, Corning, N.Y.) at 37°C in an atmosphere of 5% CO2. HUC were cultured in i%FBS-F12+, a medium that contained fetal bovine serum (GIBCO BRL, Gaithersburg, Md.) and Ham's F12 medium (GIBCO BRL) and that was developed for this cell type (43) . NIH 3T3, T24, and 647V cells were cultured in 10%CS-F12, a medium that contained calf serum (GIBCO BRL) and Ham's F12 medium.
Plasmids. As shown in Fig. 1 , in plasmid pSV2Neo, the expression of the G418r Neo gene is driven by the SV40 early gene promoter derived from a PvuII-HindIII fragment of the SV40 ori (50) . Three functions are encoded by this PvuIIHindIII region, the early gene promoter, the late gene promoter, and the ori. This PvuII-HindIII region also contains three SV40 T-antigen-binding sites (46 (42) . Although there was some variation in the transformation frequency among these T-SV-HUC, the overall effi- (Table 1) . Therefore, whatever property prevented efficient G418r transformation by pSV2Neo in CK/SV-HUC2 and SV-HUC was altered in the tumorigenic derivatives, T-SV-HUC, and was not present in the control cell lines, which do not contain SV40 T antigen. Efficient transient Neo gene expression from pSV2Neo in SV-HUC. We addressed the possibility that SV40 T antigen (or some other cellular factor) downregulates the expression of the Neo gene from the SV40 early promoter in pSV2Neo in SV-HUC but not in the tumorigenic derivatives. We compared gene expression from pSV2Cat (a vector in which the Cat gene was substituted for the Neo gene) in SV-HUC with that in a representative isogenic tumorigenic derivative of SV-HUC, mTT1. Transient gene expression studies showed no difference in CAT expression between the cell line that was efficiently transformed by pSV2Neo and the cell line that was inefficiently transformed (Fig. 2) . These results are inconsistent with the hypothesis that the failure to recover G418r colonies after transfection of SV-HUC with pSV2Neo results from poor Neo gene expression in this cell line.
Efficient G418r transformation of SV-HUC by ori-Neo constructs. SV40 T antigen interacts with its ori, affecting DNA replication as well as gene transcription (17, 22, 23, 41) . To address the possibility that differences between the nontumorigenic and tumorigenic SV40-immortalized cells in this interaction could explain their different G418r transformation efficiencies with pSV2Neo, we constructed two new Neo gene vectors, G13.lNeo and G13.1'Neo, each with a different mutation in its SV40 ori (Fig. 1) . The replicationdefective mutation in G13.lCat (the same as that in G13.lNeo) apparently did not interfere with transcription promotion activity, as determined by a transient expression assay (Fig. 2) . With these vectors, there was no difference in Results of the CAT assay that was used to determine whether there are differences in CAT expression between wild-type (pSV2Cat) and mutant (G13.lCat) SV40 promoters in two cell lines, SV-HUC and mTT1. There were no differences in expression levels between the cell lines (compare lanes 3 to 6). pBR322 (with no Cat gene) was used as a negative control (lanes 1 and 2).
G418r transformation frequencies between pSV2Neo and the three control cell lines, which do not contain the SV40 genome (Table 1) . Therefore, G418' transformation with our ori-constructs was equivalent to that with the pSV2Neo construct. There was also no difference in the ability to cause G418r transformation of T-SV-HUC between the oriconstructs and pSV2Neo (Table 1 ). In contrast, the G418r transformation efficiencies for both SV-HUC and CK/SV-HUC2 were significantly increased when the ori-constructs were used to introduce the Neo gene (Table 1) . Thus, the phenomenon of inefficient G418' transformation of SV-HUC and CK/SV-HUC2 by pSV2Neo that we had observed requires the presence of a wild-type SV40 ori.
Inhibition in trans of efficient G13.1Neo-mediated G418F transformation of SV-HUC by a wild-type ori-containing plasmid. To further confirm that a wild-type SV40 ori was a required factor in the poor transformation frequencies for SV-HUC and CK/SV-HUC2, we performed a mixed transfection experiment in which we tested the ability of the wild-type SV40 ori to interfere with efficient G418' transformation of SV-HUC by ori-constructs. In these experiments, the frequencies of G418r transformation of SV-HUC and mTT1 by G13. lNeo were compared with the frequencies obtained when a vector containing a wild-type SV40 ori was added to the transfection mixture. The G418' transformation frequencies for both SV-HUC and CK/SV-HUC2 decreased in a dose-dependent manner with increasing concentrations of such a vector, e.g., pSV2Cat (Fig. 3A) . The deleterious effect of the wild-type SV40 ori on the G418r transformation of SV-HUC by G13.1Neo did not depend on the gene encoded in the plasmid vector, because it was observed in experiments with constructs that did not encode any gene (Fig. 3B) . Importantly, a wild-type SV40 ori had no effect in trans on G418' transformation by G13.lNeo of the tumorigenic SV-HUC derivative mTT1 (Fig. 3) Replication of pSV2Neo in SV-HUC but not T-SV-HUC. In the presence of a wild-type SV40 ori, T antigen stimulates DNA replication (10, 22, 47) . We tested the possibility that pSV2Neo plasmid replication occurred in SV-HUC but not T-SV-HUC. To distinguish bacterial plasmid DNAs that were transfected into the cells from plasmid DNAs that were replicated by the host mammalian cells, we made use of the sensitivity of bacterially replicated plasmid DNAs to the restriction enzyme DpnI, which results from dam methylation of GATC sequences by bacteria (13, 25) . SV (Fig. 4, lanes 1 to 3) . On the other hand, the quantity of pSV2Neo DNA did not increase in mTT1 in 3 days following transfection, and this DNA was sensitive to DpnI digestion (Fig. 4, lanes 7 to 9) . The quantity of plasmid DNA did not increase in either cell line when the ori-construct G13.lNeo was used (Fig. 4 , lanes 4 to 7 and 11 to 13). This experiment was also done with CK/SV-HUC2 and all the other T-SV-HUC ( SV40 T-antigen mutations in T-SV-HUC. The failure of pSV2Neo to be replicated in T-SV-HUC could be explained by replication-defective mutations in the T-antigen gene. To test this hypothesis, we examined the status of T antigen and the T-antigen gene in the SV40-immortalized cell lines and the tumorigenic derivatives used in this series. We first used Western blotting to study T antigen. All the nontumorigenic and tumorigenic SV40-immortalized cells in both of our transformation systems (8, 21) contained SV40 small t and large T antigens (data not shown). Also, most of the tumorigenic derivatives contained an additional protein that reacted with antibodies to SV40 T antigen (Fig. 5) . This additional band could be detected with two different antibodies recognizing different epitopes of T antigen (see Materials and Methods). It was approximately 100 kDa in size (authentic large T antigen is 94 kDa in size) and was therefore similar in size to the super T antigen described for SV40-transformed mouse cells (30) . This super T antigen was observed in all T-SV-HUC, except for mTT1 and T9. T7, Tll, and T16 also contained other, larger proteins that reacted with only one antibody to SV40 T antigen. However, in this study, we characterized only the 100-kDa super T antigen. The correlation between these altered T antigens in the T-SV-HUC and the observed failure to replicate pSV2Neo was good, except for mTT1 and T9 (Fig. 5, lanes   2 and 6) .
We therefore sequenced the T antigens of mTT1 and T9 to determine whether the T-antigen genes in these cell lines had sustained other types of mutations that would alter DNA replication. A PCR technique was used to amplify the SV40 T-antigen coding region from SV-HUC, mTT1, and T9 with two set of primers (see Materials and Methods). The first set of primers encompassed the 5' part of SV40 early transcripts from nucleotides 3540 to 5199 (Fig. 6a) . PCR amplification with this set of primers resulted in two products that were separated into two bands by 1% agarose gel electrophoresis. These two PCR products were derived from the authentic SV40 early transcripts for the large T and small t antigens. SV-HUC, mTT1, and T9 contained two authentic SV40 early transcripts, as shown by these two bands (Fig. 6b) . The second set of primers encompassed the 3' part of SV40 early transcripts from nucleotides 2652 to 3615. PCR amplification with this set of primers revealed only one PCR product derived from the RNAs of SV-HUC, mTT1, and T9 (data not shown). The PCR products were cloned into a V vector and 6 . PCR amplification of SV40 early transcripts. SV40 large T and small t antigens were encoded by the same SV40 early transcripts but with different splicing events (a). For examination of these transcripts in our cell lines, PCR amplification of SV40 early transcripts was done with an upstream primer, 5199 (20-mer, from nucleotides 5180 to 5199), and a downstream primer, 3540 (20-mer, from nucleotides 3540 to 3559). The wild-type viral genes yielded two products, one for SV40 large T antigen and one for small t antigen, in all cell lines examined (b). Both of these bands were present in all cell lines tested. In addition, the T7 cell line contained an additional band between the two bands for authentic large T and small t antigens, corresponding to super T antigen. The molecular weight marker (MW) was A DNA digested with the restriction enzyme BstEII.
sequenced (see Materials and Methods). As shown in Fig. 7 , the SV40 T antigen in mTT1 contained one point mutation at codon 221, from TTA (Leu) to TIT (Phe), which is located in the SV40 ori DNA-binding domain (38) . T9 contains four copies of the SV40 genome (as estimated by Southern blot analysis; data not shown). To date, we have sequenced four clones of PCR products from each set of primers described above and have not yet identified a T-antigen mutation in T9. In summary, T-antigen mutations that inactivate SV40 ori have been identified in all but one T-SV-HUC. SV40 super T antigen results from a 147-bp repeat in the 5' end of T antigen. To confirm and characterize the altered super SV40 T-antigen transcript identified (above) in most of the tumorigenic cell lines, we first analyzed the 5' end of SV40 early transcripts from a representative T-SV-HUC in this series, T7, by using a PCR technique. This PCR analysis revealed a third SV40 early transcript in addition to the two authentic transcripts (Fig. 6b) . We hypothesized that this additional SV40 early transcript might encode super T antigen. Cloning and sequencing of this altered SV40 early transcript revealed a 147-bp (49-amino-acid) repeat extending from codons 83 to 132. The remaining 3' end of the T7 SV40 early transcript was also sequenced by use of the same technique and shown to contain no mutations.
DISCUSSION
While using the pSV2NTeo vector as a vehicle for the selectable marker gene Neo in oncogene transfection exper-T7 (2) mTT1 ( iments, we fortuitously observed a highly significant difference in G418' transformation frequencies between SV40-immortalized HUC (SV-HUC) and their chemically induced tumorigenic derivatives (T-SV-HUC) ( Table 1) . We systematically pursued a mechanistic explanation for this difference, as reported here. First, the observation that pSV2Neo is inefficient in G418r transformation of SV-HUC led us to the discoveries that plasmid vectors, such as pSV2Neo, containing SV40 ori are replicated extensively when transfected into cells that contain a wild-type T antigen (Fig. 4) and that this replication is associated with poor transformation frequencies (Table 1 and Fig. 3 ). This finding has practical significance in that it demonstrates that expression elements containing SV40 ori, such as pSV2Neo, may not be suitable for some SV40-immortalized cells. A simple replacement of the wild-type ori with a mutant ori, however, corrects the problem (Table  1 and Fig. 3) .
Second, the observation that pSV2Neo is not replicated in tumorigenic derivatives of SV-HUC, T-SV-HUC, but does efficiently transform these cells to G418r (Table 1 and Fig. 4 ) led us to the discovery that T-SV-HUC sustained mutations in their T-antigen genes that would affect their abilities to initiate DNA replication from SV40 ori. The T-antigen mutations that we characterized were of two types. Western blot analysis revealed several T antigens of different sizes (Fig. 5 ) similar to those observed in rodent cells, including 100-, 115-, and 145-kDa altered T antigens (30, 33, 35) . These altered T antigens are not only defective for but also interfere with wild-type T-antigen ori function (9, 16, 36) . One of the altered T antigens found in our studies, the 100-kDa T antigen, was present in most T-SV-HUC. This altered T antigen was similar in size to the super T antigen observed by Levitt et al. in SV40-transformed mouse cells (30) . We cloned and sequenced this candidate super T antigen from a representative T-SV-HUC, T7 ( Fig. 6 and 8 ). This first example of a human SV40 super T antigen contains a duplication of 49 amino acids from codons 83 through 132 in the T-antigen gene (Fig. 8) . It is interesting that codons 132 and 133 contain the same sequence as the splicing donor region of SV40 T antigen: AGGTA (Fig. 8) reported a coding sequence for a 100-kDa super T antigen that contained two integrated partial repeats of the SV40 genome ( Fig. 9) (30) . It is possible that a similar partial repeat of the SV40 genome exists in most of our tumor cell lines, and this rearrangement produces super T antigen by two splicing events, as proposed in Fig. 9 . Super T antigen has been identified in several cell types that are nonpermissive or semipermissive for SV40 and has been implicated to interfere with the replicative function of T antigen (9, 16, 36) . Our data suggest that super T antigen may play a similar role in our SV-HUC transformation system (8) . In this respect, we note that most of the tumor cell lines have multiple copies of the T-antigen gene (20a) and also contain an apparently normally sized T antigen. Thus, the proposed role of SV40 super T antigen in our system would necessarily be of a transdominant nature.
Super T antigen was not detected by Western blotting in two tumor cell lines, mTT1 and T9 (Fig. 5) , that showed efficient pSV2Neo G418r transformation. We examined the T-antigen gene in these two cell lines for other types of T-antigen mutations. mTT1 contains only one copy of the SV40 genome (unpublished Southern blot data). Sequencing showed that this single copy of the SV40 genome in mTT1 has sustained an A -k T transversion mutation (Fig. 7) Super T- ag  FIG. 9. (a) Model for the formation of super T antigen (30) , in which two integrated partial repeats of SV40, a truncated early region followed by a complete early region in the same orientation, combine to make the transcript for the 100-kDa super T antigen. (b) Our super T antigen also contains a duplication (from codons 83 through 131) and could be generated by two splicing events. The first, normal SV40 splicing event connects codon 82 to codon 83 in the 5' end. The second splicing event connects codon 131 in the 5' part of the repeat to codon 83 in the 3' part of the repeat.
system is by interfering with SV40 T-antigen-activated SV40 DNA replication and resultant cell damage and death. However, this interpretation does not explain why such mutations were only present in tumorigenic cells and not in immortal cells. One possibility is that the generation of super T antigen occurred in response to the carcinogen treatment that was part of the transformation protocol that generated T-SV-HUC (42) . Extensive data demonstrate that carcinogens stimulate unscheduled DNA synthesis of integrated viral DNA sequences as well as cellular DNA sequences. Autoreplication of SV40 sequences during unscheduled DNA synthesis could lead to amplification of viral DNA sequences (26, 28) . Such amplification could be deleterious to cell survival. The generation of mutations, such as super T antigen, that damper SV40 DNA synthesis during carcinogen-induced unscheduled DNA synthesis would give such cells a selective survival advantage. Alternatively, the mutant T antigens identified were more oncogenic than the wild-type T antigen. It would be possible to address this question by transfecting the mutant T antigens into SV-HUC and testing the tumorigenicity of the transformants.
The T-SV-HUC carcinogen-induced tumorigenic transformants used in this system show highly significant nonrandom genetic losses similar to those observed in clinical bladder cancers, including losses of genes on chromosomes 3p, llp, 13q, and 18q (55), as well as activation of Ha-ras by a point mutation (20a) . Our studies have showed that the chemicals that are transforming in this system are also mutagenic in the cells that they transform (1, 2) . Therefore, we have hypothesized that a mechanism by which chemical carcinogens contribute to SV-HUC tumorigenic transformation involves causing activating mutations in oncogenes or inactivating mutations in suppressor genes (2) . The present data do not contradict this hypothesis. However, they indicate that the SV40 T-antigen gene may also be an important target for mutagenesis in tumorigenic transformation of cells containing SV40. These data also provide the first example of an SV40 super T antigen in human cells and the first example of T-antigen mutations in a HUC transformation system.
